STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2055 by analyst upside · 2026-08-13
KNSA
Kiniksa Pharmaceuticals International, plc
Healthcare · Market Cap $6B · P/E 78.9x
ANALYST PRICE TARGET
+25.4%
implied upside to consensus target
Current Price $78.15
Consensus Target $98.0
Bull Target $108.0
Bear Target $87.0
Analysts Covering 8
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
7
Hold
0
Sell
0
52-Week Low $32.69
52-Week High $82.94
YTD Return +86.0%
FUNDAMENTALS
Market Cap $6B
P/E Ratio (TTM) 78.9x
Forward P/E 48.3x
EPS (TTM) $0.99
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $841M
Profit Margin 9.6%
52-WEEK RANGE
52-Week Low $32.69
52-Week High $82.94
Current Price $78.15
Bear Target $87.0
Bull Target $108.0
● Now $78.15 ● Target $98.0
TRADING DATA
Avg Volume 757K
YTD Return +86.0%
Analyst Count 8
Consensus Buy
Upside to Target +25.4%
Last Updated 2026-08-13

ANALYST SUMMARY

Kiniksa Pharmaceuticals International, plc (KNSA) is currently trading at $78.15 with a Wall Street consensus price target of $98.0, implying potential upside of 25.4% over the next 12 months. 8 analysts currently cover KNSA, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $108.0, while the most cautious has a target of $87.0.

KNSA operates in the Healthcare sector with a market capitalisation of $6B. The stock is up 86.0% year-to-date and is currently trading near the upper end of its 52-week range of $32.69 – $82.94.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for KNSA, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Canaccord Genuity - Reiterated
Buy → Buy 2026-04-29 Building track record
Citigroup - Reiterated
Buy → Buy 2026-04-29 Building track record
Wedbush - Reiterated
Outperform → Outperform 2026-04-29 Building track record
Wells Fargo - Reiterated
Overweight → Overweight 2026-04-29 Building track record
Jefferies - Reiterated
Buy → Buy 2026-04-28 50% win rate (6 calls)
Wedbush - Reiterated
Outperform → Outperform 2026-04-16 Building track record
Wells Fargo - Reiterated
Overweight → Overweight 2026-02-25 Building track record
Wedbush - Reiterated
Outperform → Outperform 2026-02-25 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
69
out of 100
Coverage depth
17/30
Consensus clarity
25/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →